Latin America Health Times
SEE OTHER BRANDS

Keeping up with healthcare and wellness news from Latin America

Latin America Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Latin America Health Times.

Press releases published on April 14, 2025

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory diseases (“Can-Fite” or the …

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

WARREN, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announces CEO Dr. Ryan Saadi, MD, MPH, will participate in BioNJ’s Fifteenth Annual Bio Partnering Conference. Dr. Saadi will be …

31st annual Enserva STARS & Spurs Gala raises more than $1.7 million for STARS

31st annual Enserva STARS & Spurs Gala raises more than $1.7 million for STARS

CALGARY, Alberta, April 14, 2025 (GLOBE NEWSWIRE) -- The Enserva STARS …

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight

New York, USA, April 14, 2025 (GLOBE NEWSWIRE) -- Psoriasis Market Outlook in the 7MM Through 2034: In-Depth Analysis by Psoriasis Type | DelveInsight The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near …

Epilepsy Community Unites to Oppose Cuts to Crucial Federal Epilepsy Programs

Epilepsy Community Unites to Oppose Cuts to Crucial Federal Epilepsy Programs

BOWIE, Md., April 14, 2025 (GLOBE NEWSWIRE) -- The 118 undersigned organizations – representing people living with epilepsy; caregivers and loved ones; physicians, care providers, and epilepsy centers; epilepsy researchers; and others – are united in …

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders

HOUSTON, TX, April 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is pleased to announce that the United States Patent and …

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE Paris, April 14, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United …

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

AB Science reçoit un avis d’acceptation pour le brevet américain courant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS D'ACCEPTATION POUR LE BREVET AMERICAIN COUVRANT JUSQU'EN 2040 LE MASITINIB DANS LE TRAITEMENT DE LA DREPANOCYTOSE Paris, 14 avril 2025, 18h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui que …

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

STAMFORD, Conn., April 14, 2025 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”), today announced that its Board of Directors (the “Board”) has approved a 1-for-3 reverse stock split of its outstanding shares of common stock. Cara …

Valneva Receives First Marketing Authorization for IXCHIQ®  in a Chikungunya Endemic Country

Valneva Receives First Marketing Authorization for IXCHIQ® in a Chikungunya Endemic Country

Saint Herblain (France), April 14, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted marketing authorization to its single-dose vaccine IXCHIQ …

 Valneva reçoit la première autorisation de mise sur le marché pour IXCHIQ® dans un pays où le chikungunya est endémique

Valneva reçoit la première autorisation de mise sur le marché pour IXCHIQ® dans un pays où le chikungunya est endémique

Saint Herblain (France), le 14 avril 2025 - Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l'agence de santé brésilienne (ANVISA) a accordé l'autorisation de mise sur le marché à son …

Prostadine Drops Reviews [We Tested It] Read Ingredients, Side Effects for Urinary System

Prostadine Drops Reviews [We Tested It] Read Ingredients, Side Effects for Urinary System

ST. PETERSBURG, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Prostadine The Natural Solution for Prostate Health - As men age, prostate health often becomes a significant concern. The prostate, a small, walnut-sized gland in the male reproductive system, plays …

Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights

Johnson & Johnson’s Oral IL-23, Icotrokinra, Poised to Redefine the Psoriasis Treatment Landscape Following Positive Phase 3 Data, According to Spherix Global Insights

EXTON, PA, April 14, 2025 (GLOBE NEWSWIRE) -- Johnson …

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated Company aims to accelerate access to much-needed biosimilar to …

Positron Corporation Secures Agreement to  Sell Four PET-CT Scanners

Positron Corporation Secures Agreement to Sell Four PET-CT Scanners

Niagara Falls, NY, April 14, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical services, is pleased to …

Milwaukee's Underserved Communities Benefit from Outreach Community Health Center’s Use of the CHESS Health Platform

Milwaukee's Underserved Communities Benefit from Outreach Community Health Center’s Use of the CHESS Health Platform

Rochester, New York, April 14, 2025 (GLOBE NEWSWIRE) -- CHESS Health proudly announces a partnership with Outreach Community Health Centers (OCHC), a Federally Qualified Health Center (FQHC) based in Milwaukee, Wisconsin. This partnership is particularly …

Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month

Free Oral Cancer Screenings in Honor of Oral, Head and Neck Cancer Awareness Month

IRVING, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- In honor of Oral, Head and Neck Cancer Awareness Month, 26 U.S. Oral Surgery Management surgeon partners in seven states will offer free oral cancer screenings during the week of April 14. The screenings …

VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma

VIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin Lymphoma

— Innovative ethanol-free formulation intended to provide improved safety and advance care for patients undergoing high-dose conditioning therapy prior to autologous hematopoietic cell transplantation (AHCT) — First patient dosed at City of Hope National …

NeuroOne® OneRF® Technology Success Story Featured on Fox News

NeuroOne® OneRF® Technology Success Story Featured on Fox News

Pediatric Patient Treated with OneRF® Ablation System Goes From Up to 10 Nightly Seizures to Zero EDEN PRAIRIE, Minn., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical …

Regional Health Properties Reports Fourth Quarter & Full Year 2024 Financial Results

Regional Health Properties Reports Fourth Quarter & Full Year 2024 Financial Results

ATLANTA, GA, April 14, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPB) (OTCQB: RHEPA), a self-managed healthcare real estate investment company that invests primarily …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service